Log inSign up
Image
user avatar
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein
Breast cancer specialist and professor @DanaFarber Cancer Institute and @HarvardMed. Tweets are my own and not medical advice. COI disclosure: no COI.
Boston, MA
dana-farber.org
Joined July 2015
573
Following
14.5K
Followers
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    May 2, 2018
    The "best solution" is not to hire scribes, human or robotic. The best solution is to move away from a health system based on outrageous documentation for billing purposes that swamps the "care" given to people.
    user avatar
    Bob Wachter
    @Bob_Wachter
    Apr 30, 2018
    My new piece in @WSJ: the #EHR has turned doctors into expensive & unhappy data entry clerks. Best solutions to date: scribes. But digital scribes – combining advances in #AI & voice recognition – may yet save the day on.wsj.com/2vWoOSJ @WSJhealth @WSJTech @UCSF @augmedix
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Nov 6, 2018
    Great article but misses one big thing. Docs think EHR is for them. IT folks think it is for patient. Both are wrong. EHR is for hospital finance and administration as command/control and billing systems. Most of the challenges stem from that reality.
    user avatar
    Atul Gawande
    @Atul_Gawande
    Nov 5, 2018
    My latest @NewYorker piece, in gestation for a couple years now, as you’ll see. Something to read about other than the election, at least. It is on the state of health care information technology. In other words: newyorker.com/magazine/2018/….
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Dec 24, 2018
    The wine for academics. From Portugal.
    Image
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    May 25, 2021
    Top breast cancer abstracts @ASCO #asco2021 @OncoAlert
    Image
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Mar 7, 2021
    Important study in impact of interrupting mammography during pandemic
    user avatar
    Antonio Giordano, MD PhD
    @antgiorda
    Mar 6, 2021
    Breast cancer does not go in lockdown. #bcsm Increase in Diagnosis of Node-Positive and Stage III Breast Cancer After Screening Interruption Due to the #Covid19 Pandemic - The ASCO Post ascopost.com/news/march-202…
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Oct 7, 2019
    .⁦@NobelPrize⁩ selfie. ⁦@DrChoueiri⁩ ⁦@kaelin_lab awesome. So happy for Bill, his family and ⁦@DanaFarber⁩ and ⁦@harvardmed⁩
    Image
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Mar 8, 2018
    A nurse in remote Australia diagnosed his own MI by EKG, placed his own IV, and treated himself successfully. But it took 3 authors to write the NEJM letter!
    Image
    nejm.org
    Self-Management of an Inferior ST-Segment Elevation Myocardial Infarction | NEJM
    Severe chest pain and dizziness developed in a 44-year-old nurse, the only medical professional at a remote post in Australia. He obtained his own ECG, which showed ST-segment elevation myocardial ...
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Dec 23, 2020
    A stocking stuffer for the holidays. My review on ER+ breast cancer. Includes comment on adjuvant CDK4/6i and and RxPonder data. nejm.org/doi/full/10.10…
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Jun 23, 2021
    Beautiful paper in this week’s @nejm from ⁦@DanaFarber⁩ colleagues ⁦@DrMarkAwad⁩ ⁦@KevinHaigisLab⁩ Andrew Aguirre, Brian Wolpin, Pasi Janne, and others on molecular resistance to KRAS inhibitors
    Image
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Jun 5, 2022
    So trastuzumab deruxtecan is the most active single drug in metastatic HER2 positive tumors, and the most active in TNBC. And very active in ER+ HER2 low too. Impressive data from destiny breast04.
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Mar 10, 2020
    Since a lot of breast cancer patients have asked: Hormonal therapies (tamoxifen, fulvestrant, and aromatase inhibitors such as letrozole, anastrozole, and exemestane) do NOT weaken or affect your immune system. No "extra" need for concern amidst the coronavirus outbreak.
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Aug 22, 2019
    Very cool moment as @redsox ask players and fans to stand a show placards with names of people they know affected by cancer. The point is: everyone has friends and family affected by cancer. Proud to be helping through @DanaFarber
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Oct 31, 2023
    60% of medical students say they anticipate a career not seeing patients. a) we are facing a huge physician shortage b) then what’s the point of going to med school? c) schools + hospitals have failed to make being a doctor satisfying work for many
    stethoscope
    1 in 4 US medical students consider quitting, most don’t plan to treat patients: report
    From thehill.com
    117K
  • user avatar
    Harold J. Burstein, MD, PhD, FASCO
    @DrHBurstein
    Dec 1, 2017
    Nice example of the pitfalls of subset analyses. In the STAMPEDE trial, patients diagnosed on Monday did not get benefit from treatment. See editorial by Spears in @Annals_Oncology 2017;28:2327
    Image